“The Morgan’s report states that US application number 16/636,545 is Paradigm’s core patent. This is incorrect. Paradigm’s core patents are three granted patents as per the table below. The three foundational patents are ALL GRANTED. As we have previously discussed, a third party seeking to treat osteoarthritis in the presence of BME will infringe these patents. This is not dependant on this patent application 16/636,545 being granted.”
This is really really obvious stuff covered in previous releases by the company and in various presentations and discussed on HC exhaustively…
BME is present in all serious cases of OA. Anyone trying to use pps to treat OA without treating BME is asking to be sued, not to mention the whole idea of treating OA but not BME so as to not infringe on a patent is ridiculously impossible.
Ann: Clarification of recent analyst report on Patent Protection, page-14
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.5¢ | 28.5¢ | $78.74K | 270.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 76 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 26392 | 6 |
View Market Depth
| Last trade - 15.09pm 08/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |